| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-03-12 | PLX-PAD Cells (Placental eXpanded cells) | tendon injury | preclinical | Pluristem Therapeutics (Israel) | |
| 2014-03-11 | Nexavar® (sorafenib) | hepatocellular carcinoma |
3 | Bayer HealthCare (Germany) Onyx Pharmaceuticals, an Amgen subsidiary (USA) | Cancer - Oncology |
| 2014-03-11 | H4+IC31® (AERAS-404) | tuberculosis | 2 | Aeras (USA) | Infectious diseases |
| 2014-03-11 | human heterologous liver cells (Heparesc) | Urea Cycle Disorders (UCD) in children | Cytonet (Germany - USA) | Metabolic diseases - Genetic diseases | |
| 2014-03-10 | O304 | NASH (non-alcoholic steatohepatitis) |
1 | Betagenon (Sweden) Baltic Bio(Sweden) | Metabolic diseases - Liver diseases - Cardiovascular diseases |
| 2014-03-10 | Mitizax® (immunotherapy tablet) | house dust mite induced hay fever and asthma | 2-3 | ALK Abello (Denmark) Torii Pharmaceutical (Japan) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2014-03-08 | RHB-102 (extended-release (24 hours) formulation of ondansetron) | prevention of nausea and vomiting in cancer patients |
RedHill Biopharma (Israel) | Cancer - Oncology | |
| 2014-03-06 | Myrcludex B | hepatitis B | 2a | Hepatera (Russia) | Infectious diseases |
| 2014-03-06 | human induced pluripotent stem cells (hiPSCs) platform | Fate Therapeutics (USA - CA) | Neuromuscular diseases - Rare diseases - Technology - Services | ||
| 2014-03-06 | faldaprevir (BI 201335) in combination with peginteferon and ribavirin | HCV/HIV co-infection |
3 | Boehringer Ingelheim (Germany) | Infectious diseases |
| 2014-03-05 | lebrikizumab | severe uncontrolled asthma | 2b | Roche (Switzerland) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2014-03-05 | Epi proColon® 2.0 CE (septin9 test) | colorectal cancer detection | Epigenomics (Germany - USA) | Cancer - Oncology | |
| 2014-03-05 | Glassia® (alpha-1 antitrypsin) | type 1 diabetes | 2-3 | Kamada (Israel) | Metabolic diseases |
| 2014-03-04 | Raxone® (idebenone) | Leber's Hereditary Optic Neuropathy (LHON) |
expanded access program | Santhera Pharmaceuticals (Switzerland) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2014-03-04 | simeprevir (TMC435) and daclatasvir | treatment-naïve or previous null responder patients with Hepatitis C Virus (HCV) genotype 1a and 1b | 2 | BMS (USA) Medivir (Sweden) | Infectious diseases |
| 2014-03-04 | KamRAB® | post-exposure prophylaxis (PEP) for rabies | 2-3 | Kamada (Israel) | Infectious diseases |
| 2014-03-04 | gevokizumab | erosive osteoarthritis of the hand (EOA) |
2 | Xoma (USA - CA) | Inflammatory diseases - Rheumatic diseases |
| 2014-03-03 | brexpiprazole (7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one) | major depressive disorder (MDD) |
3 | Lundbeck (Denmark) Otsuka Pharmaceutical (Japan) | CNS diseases - Mental diseases |
| 2014-03-03 | MetMAb (onartuzumab) | previously-treated advanced non-small cell lung cancer | 3 | Roche (Switzerland) | Cancer - Oncology |
| 2014-02-28 | SYN120 | Alzheimer's disease |
2 | Biotie Therapies (Finland) | CNS diseases - Neurodegenerative diseases |
